for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chimerix Inc

CMRX.OQ

Latest Trade

2.08USD

Change

0.04(+1.96%)

Volume

63,476

Today's Range

2.04

 - 

2.13

52 Week Range

1.25

 - 

4.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Chimerix Reports Q3 Loss Per Share Of $1.26

Nov 5 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE.Q3 LOSS PER SHARE $1.26.Q3 REVENUE $2.0 MILLION VERSUS $400,000.

Chimerix Announces Exclusive Global License Agreement With Symbio Pharma For Brincidofovir

Sept 30 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SYMBIO PHARMACEUTICALS FOR BRINCIDOFOVIR.CHIMERIX INC- CHIMERIX TO RECEIVE UP TO $180 MILLION IN POTENTIAL CLINICAL, REGULATORY, AND COMMERCIAL MILESTONES AND IS ELIGIBLE FOR DOUBLE DIGIT ROYALTIES.

Chimerix Reports Q2 Loss Per Share $0.35

Aug 8 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL UPDATE.Q2 LOSS PER SHARE $0.35.Q2 REVENUE $1.4 MILLION VERSUS $1.2 MILLION.LOOKING FORWARD TO FILING NDA FOR BRINCIDOFOVIR NEXT YEAR FOR TREATMENT OF SMALLPOX.

Chimerix Announces Exclusive Worldwide License Of CX-01 For Acute Myeloid Leukemia

July 31 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE OF PHASE 3 READY CX-01 FOR DEVELOPMENT IN ACUTE MYELOID LEUKEMIA.CHIMERIX INC - PLANS TO INITIATE PHASE 3 REGISTRATIONAL TRIAL IN MID-2020.CHIMERIX INC - COMPANY PLANS TO INITIATE PHASE 3 REGISTRATIONAL TRIAL IN MID-2020.CHIMERIX - HAS EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE CX-01.CHIMERIX INC - WILL MAKE AN UPFRONT PAYMENT OF $30 MILLION TO CANTEX.CHIMERIX INC - HAS ISSUED 10 MILLION SHARES OF CHIMERIX COMMON STOCK TO CANTEX.CHIMERIX INC - CANTEX IS ELIGIBLE FOR REGULATORY AND COMMERCIAL MILESTONES OF UP TO $587.5 MILLION, TIERED ROYALTIES STARTING AT 10%.

Chimerix Reports Q1 Loss Per Share Of $0.35

May 9 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND STRATEGY UPDATE.Q1 LOSS PER SHARE $0.35.Q1 EARNINGS PER SHARE ESTIMATE $-0.35 -- REFINITIV IBES DATA.Q1 REVENUE $2.4 MILLION VERSUS $800,000.RESTRUCTURING TO REDUCE WORKFORCE BY MORE THAN 50%, MAINTAINING KEY CAPABILITIES AND PRESERVING CAPITAL FOR NEW PROGRAMS.PLAN TO FOCUS ON EXECUTION OF SMALLPOX PROGRAM, HALTING ALL OTHER BRINCIDOFOVIR DEVELOPMENT ACTIVITIES.REPORTS POSITIVE TOP-LINE SURVIVAL DATA FROM PIVOTAL MOUSE STUDY AS KEY MILESTONE ON PATH TO SMALLPOX REGULATORY SUBMISSION.CHIMERIX - DISCONTINUATION ONGOING HUMAN CLINICAL TRIALS FOR ORAL AND INTRAVENOUS BRINCIDOFOVIR DUE TO LOW PATIENT ACCRUAL ACROSS ALL ACTIVE TRIALS..INTENDS TO PURSUE EXTERNAL OPPORTUNITIES TO BUILD ITS PIPELINE OF PRODUCT CANDIDATES.

Chimerix Says Contravir Pharmaceuticals Intends To Terminate License Agreement

April 4 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX -ON APRIL 2 CO RECEIVED NOTIFICATION FROM CONTRAVIR PHARMACEUTICALS OF ITS INTENTION TO TERMINATE LICENSE AGREEMENT BETWEEN CO AND CONTRAVIR.CHIMERIX INC - LICENSE AGREEMENT BY AND BETWEEN COMPANY AND CONTRAVIR, DATED DECEMBER 17, 2014.CHIMERIX INC - TERMINATION OF LICENSE AGREEMENT WILL BE EFFECTIVE ON JUNE 1, 2019.CHIMERIX INC - CONTRAVIR MADE DECISION TO TERMINATE LICENSE AGREEMENT FOLLOWING ITS DECISION TO NO LONGER PURSUE DEVELOPMENT OF CMX157.CHIMERIX INC - UPON EFFECTIVENESS OF TERMINATION OF LICENSE AGREEMENT, COMPANY WILL REACQUIRE ALL WORLDWIDE RIGHTS TO CMX157.

Chimerix Inc - Michelle Berrey To Step Down As Chief Executive Officer

Feb 6 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES MANAGEMENT TRANSITION.CHIMERIX INC - M. MICHELLE BERREY, M.D., M.P.H., HAS RESIGNED FROM HER ROLE AS CHIMERIX PRESIDENT AND CHIEF EXECUTIVE OFFICER.CHIMERIX INC - MICHELLE BERREY TO STEP DOWN AS CHIEF EXECUTIVE OFFICER.CHIMERIX - GARRETT NICHOLS, TIMOTHY TROST, MICHAEL ALRUTZ APPOINTED MEMBERS OF NEWLY CREATED OFFICE OF CEO, ON INTERIM BASIS UNTIL REPLACEMENT FOUND.

Chimerix Q3 Loss Per Share $0.33

Nov 8 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.33.Q3 REVENUE $400,000 VERSUS $900,000.Q3 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $974,000 -- THOMSON REUTERS I/B/E/S.

Chimerix Q2 Loss Per Share $0.39

Aug 8 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.39.Q2 REVENUE $1.2 MILLION VERSUS $700,000.Q2 REVENUE VIEW $950,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.INTENDS TO SUBMIT MARKETING APPLICATIONS FOR SMALLPOX FOLLOWING COMPLETION OF RABBIT AND MOUSE EFFICACY STUDIES.BALANCE SHEET AT JUNE 30, 2018 INCLUDED $195.7 MILLION OF CAPITAL AVAILABLE TO FUND OPERATIONS.

Chimerix Receives Orphan Drug Designation From The FDA For Brincidofovir For The Treatment Of Smallpox

June 7 (Reuters) - Chimerix Inc <CMRX.O>::CHIMERIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE FDA FOR BRINCIDOFOVIR FOR THE TREATMENT OF SMALLPOX.CHIMERIX - U.S. FDA GRANTED ORPHAN DRUG DESIGNATION FOR BRINCIDOFOVIR FOR TREATMENT OF SMALLPOX.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up